Drugging the Unmeasurable

From endometriosis to menopause, some of the most common women's health conditions remain inadequately measured, modelled, and treated. The problem isn’t just a lack of therapeutics — it’s a lack of consensus on which outcomes matter, what data is meaningful, and how to translate lived experience into clinical evidence. This session explores the hidden infrastructure problem behind women’s health innovation. Cyclana Bio's Lea Wenger, OvartiX's Stasa Stankovic, and one additional health innovator will discuss: What happens when medicine tries to drug diseases it still can’t properly quantify? And how do founders, clinicians, researchers, and regulators build better pathways for therapeutics in conditions medicine has long treated as “unmeasurable”?